IONM vs. QNRX, GMVDF, INVO, STSS, AEMD, RSLS, DYNT, TNON, VERO, and BJDX
Should you be buying Assure stock or one of its competitors? The main competitors of Assure include Quoin Pharmaceuticals (QNRX), G Medical Innovations (GMVDF), INVO Bioscience (INVO), Sharps Technology (STSS), Aethlon Medical (AEMD), ReShape Lifesciences (RSLS), Dynatronics (DYNT), Tenon Medical (TNON), Venus Concept (VERO), and Bluejay Diagnostics (BJDX). These companies are all part of the "surgical & medical instruments" industry.
Quoin Pharmaceuticals (NASDAQ:QNRX) and Assure (NASDAQ:IONM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, community ranking, earnings, institutional ownership, analyst recommendations, risk and profitability.
Quoin Pharmaceuticals currently has a consensus price target of $4.00, suggesting a potential upside of 422.81%. Assure has a consensus price target of $4.00, suggesting a potential upside of 732.47%. Given Quoin Pharmaceuticals' higher possible upside, analysts clearly believe Assure is more favorable than Quoin Pharmaceuticals.
Quoin Pharmaceuticals has higher earnings, but lower revenue than Assure.
Quoin Pharmaceuticals received 2 more outperform votes than Assure when rated by MarketBeat users. Likewise, 55.56% of users gave Quoin Pharmaceuticals an outperform vote while only 27.27% of users gave Assure an outperform vote.
Quoin Pharmaceuticals has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500. Comparatively, Assure has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500.
8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.3% of Assure shares are owned by institutional investors. 3.3% of Quoin Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of Assure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Assure had 7 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 7 mentions for Assure and 0 mentions for Quoin Pharmaceuticals. Quoin Pharmaceuticals' average media sentiment score of 0.22 beat Assure's score of 0.00 indicating that Assure is being referred to more favorably in the news media.
Assure's return on equity of -107.57% beat Quoin Pharmaceuticals' return on equity.
Summary
Quoin Pharmaceuticals beats Assure on 7 of the 13 factors compared between the two stocks.
Get Assure News Delivered to You Automatically
Sign up to receive the latest news and ratings for IONM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IONM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
